Physician

Oday Saeed, M.D.

According to 2025 Medicare claims, Oday Saeed, M.D. (NPI: 1639432164) practices nephrology in the El Centro, CA market, with the plurality of this provider's patient population coming from Imperial, CA. This provider's primary affiliated billing organization is BALBOA NEPHROLOGY MEDICAL GROUP, INC. (NPI: 1316997505; TIN: 952848091) and primary practice location at 92227-7754. Saeed is affiliated with the Sharp Rees-Stealy Medical Group (ACO ID: A5521), participating under the MSSP model.

Saeed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 541 traditional Medicare patients, billed 3,223 HCPCS/CPT codes, and received $376,144 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 7,733 prescription claims across 687 beneficiaries totaling $2,424,206 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). 2023 DME data shows 33 claims. Open Payments data shows 6 records totaling $391. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $114,591 to $376,144. Similarly, Part D prescription costs have moved sharply higher in recent years, from $18,567 to $2,424,206. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $555 to $117.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	298	846	$114,591
2018	574	3,067	$334,988
2019	694	4,492	$326,493
2020	772	3,755	$340,767
2021	678	2,846	$437,789
2022	567	2,362	$380,030
2023	580	2,505	$394,330
2024	541	3,223	$376,144

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	36	146	$18,567
2016	89	245	$53,012
2017	199	569	$242,636
2018	430	3,147	$818,535
2019	550	5,262	$1,154,099
2020	690	5,854	$1,408,439
2021	766	7,878	$1,798,408
2022	612	6,776	$2,570,988
2023	613	7,053	$2,917,214
2024	687	7,733	$2,424,206

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	79	$2,163
2019	N/R	99	$4,032
2020	N/R	95	$2,821
2021	N/R	85	$3,921
2022	N/R	N/R	N/R
2023	N/R	33	$1,490
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	118	788	$283
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	86	93	$134
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	146	400	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	243	725	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	237	733	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	408	14,697	$456,007
Velphoro	Sucroferric Oxyhydroxide	100	5,160	$441,052
Farxiga	Dapagliflozin Propanediol	381	13,050	$233,919
Jardiance	Empagliflozin	269	10,008	$189,381
Kerendia	Finerenone	220	7,950	$163,127

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$391	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Oday Saeed, M.D.?

Tedicare shows public-source Medicare data for Oday Saeed, M.D. (NPI 1639432164), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Oday Saeed, M.D. have ACO affiliation data?

Oday Saeed, M.D. is shown with ACO affiliation data for Sharp Rees-Stealy Medical Group (MSSP, ACO ID A5521).

What billing organization is linked to Oday Saeed, M.D.?

Oday Saeed, M.D. is linked to BALBOA NEPHROLOGY MEDICAL GROUP, INC. (billing NPI 1316997505) in the available physician profile data.

Does Oday Saeed, M.D. have Open Payments data?

Oday Saeed, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.